Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study
- Robak T.
- Jin J.
- Pylypenko H.
- Verhoef G.
- Siritanaratkul N.
- Drach J.
- Raderer M.
- Mayer J.
- Pereira J.
- Tumyan G.
- Okamoto R.
- Nakahara S.
- Hu P.
- Appiani C.
- Nemat S.
- Cavalli F.
- Van Hoof A.
- Sheliga A.
- Teixeira A.
- Tomita A.
- Rocafiguera A. O.
- Suvorov A.
- Kuzmin A.
- Khojasteh A.
- Mezlini A.
- Golenkov A.
- Bosly A.
- Belch A.
- Van De Velde A.
- Illes A.
- Mukhopadhyay A.
- Meddeb B.
- De Prijck B.
- Garichochea B.
- Undar B.
- Gabarron C.
- Cao C.
- Souza C.
- Farber C.
- Won Suh C.
- Burcoveanu C. I.
- Cebotaru C. L.
- Truica C. -L.
- Maruyama D.
- Belada D.
- Ben Yehuda D.
- Udovitsa D.
- Dolores
- Morra E.
- Spath-Schwalbe E.
- Gonzalez-Barca E.
- Osmanov E.
- Capote F. J.
- Offner F.
- Cardenas G.
- Hess G.
- Manikhas G.
- Babu G.
- Rekhtman G.
- Rossi G.
- Marques H.
- Bumbea H.
- Wang H.
- Huang H.
- Choi I.
- Bulavina I.
- Lysenko I.
- Avivi I.
- Kryachok I.
- Zaucha J. M.
- Novak J.
- Diaz J.
- Demeter J.
- Alexeeva J.
- Zhu J.
- Vilchevskaya K.
- Ishizawa K.
- Mauricio K.
- Tobinai K.
- Ando K.
- Abdulkadryrov K.
- Shih L. -Y.
- Kuzina L.
- Gumus M.
- De Wit M.
- Capra M.
- Marques M.
- Golubeva M.
- Ojeda-Uribe M.
- Kyselyova M.
- Taniwaki M.
- Federico M.
- Crump M.
- Baccarani M.
- Ogura M.
- Egyed M.
- Udvardy M.
- Kurosawa M.
- Uike N.
- Khuageva N.
- Shpilberg O.
- Gladkov O.
- Samoilova O.
- Serduk O.
- Santi P.
- Zachee P.
- Kaplan P.
- Stoia R.
- Gressin R.
- Arranz R.
- Greil R.
- Grosicki S.
- Cancelado S.
- Nair S.
- Le Gouill S.
- Van Steenweghen S.
- Yoon S. -S.
- Chuncharune S.
- Scheider T.
- Shimoyama T.
- Liu T.
- Kinoshita T.
- Uchida T.
- Bunworasate U.
- Vitolo U.
- Pavlov V.
- Phooshkooru V. R.
- Lima V.
- Merkulov V.
- Nawarawong W.
- Hong X.
- Ke X.
- Terui Y.
- Tee Goh Y.
- Maeda Y.
- Shi Y.
- Dunaev Y.
- Lorie Y.
- Wang Z.
- Shen Z.
- Borbenyi Z.
- Gasztonyi Z.
- Masliak Z.
DOIAbstract
Background: In the LYM-3002 study, the efficacy and safety of frontline bortezomib plus rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) and rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) were compared in transplant-ineligible patients with untreated, newly diagnosed, mantle cell lymphoma. We report the final overall survival and safety outcomes for patients in the long-term follow-up phase after the primary progression-free-survival endpoint was met. Methods: LYM-3002 was a randomised, open-label, phase 3 study done at 128 clinical centres in 28 countries in Asia, Europe, North America, and South America. Adult patients with confirmed stage II–IV previously untreated mantle cell lymphoma, Ea...
Add to ORKG